{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T18:00:40Z","timestamp":1764784840917,"version":"3.37.3"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,2,18]],"date-time":"2022-02-18T00:00:00Z","timestamp":1645142400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,18]],"date-time":"2022-02-18T00:00:00Z","timestamp":1645142400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Minister of Science and Technology, R.O.C.","award":["105-2314-B-002-069-MY3 and 108-2314-B-002-140-MY3"],"award-info":[{"award-number":["105-2314-B-002-069-MY3 and 108-2314-B-002-140-MY3"]}]},{"DOI":"10.13039\/501100005762","name":"National Taiwan University Hospital","doi-asserted-by":"publisher","award":["110-P08"],"award-info":[{"award-number":["110-P08"]}],"id":[{"id":"10.13039\/501100005762","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Serum pepsinogen (PG) is recommended as a screening test for\u00a0premalignant gastric lesions. However, real-world evidence demonstrating its applicability and equivalence between different test brands is limited.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Mass screening began in 2018 in a high-risk Taiwanese population after eradication of<jats:italic>Helicobacter pylori<\/jats:italic>, with the first stage of two PG tests (GastroPanel<jats:sup>\u00ae<\/jats:sup>, Helsinki, Finland and LZ-Test<jats:sup>\u00ae<\/jats:sup>, Tokyo, Japan) and the second stage of endoscopy. A positive test was defined as PG-I\u2009&lt;\u200930\u00a0ng\/mL or PG-I\/II ratio\u2009&lt;\u20093 for GastroPanel<jats:sup>\u00ae<\/jats:sup>and PG-I\u2009\u2264\u200970\u00a0ng\/mL and PG-I\/II ratio\u2009\u2264\u20093 for LZ-Test<jats:sup>\u00ae<\/jats:sup>. Index lesions included atrophic gastritis and intestinal metaplasia. Test performance was evaluated based on the participation rate, positivity rate, referral rate, positive predictive value (PPV), and the detection rate.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among 7616 eligible participants, 5117 (67.2%) received PG tests and 284 (5.6%) tested positive. Of those who tested positive, 105 (37.0%) underwent endoscopy. Overall PPVs for atrophic gastritis and intestinal metaplasia were 12.4% and 18.9%, respectively, with detection rates of 2.5 and 3.9 per 1000, respectively. Correlations of numerical measures between tests were high and the agreements of test results were substantial. The PPVs (16.3% vs. 16.3% and 23.8% vs. 21.3%,<jats:italic>P<\/jats:italic>\u2009=\u20091.00 and 0.71, respectively), detection rates (2.5 vs. 2.5 and 3.7 vs. 3.3 per 1000,<jats:italic>P<\/jats:italic>\u2009=\u20091.00 and 0.27, respectively), and the stage distributions of gastritis were all comparable, which were confirmed by multiple regression analyses.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>PG testing is effective for mass screening after eradication of<jats:italic>H. pylori<\/jats:italic>. Tests from different manufacturers, even using different analytical methods and cutoff criteria, can perform equivalently.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12876-022-02155-7","type":"journal-article","created":{"date-parts":[[2022,2,18]],"date-time":"2022-02-18T18:05:51Z","timestamp":1645207551000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Brand interchangeability of pepsinogen tests in the real-world setting after eradication of Helicobacter pylori: a community-based study"],"prefix":"10.1186","volume":"22","author":[{"given":"Tsung-Hsien","family":"Chiang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yen-Nien","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Ru","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Hua","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun-Fu","family":"Shieh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng-Ying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Han-Mo","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hung","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chia-Tung","family":"Shun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-Shiang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaw-Town","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Chia","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,2,18]]},"reference":[{"key":"2155_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"2155_CR2","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/S0140-6736(20)31288-5","volume":"396","author":"EC Smyth","year":"2020","unstructured":"Smyth EC, Nilsson M, Grabsch HI, van Grieken NC, Lordick F. Gastric cancer. Lancet. 2020;396:635\u201348.","journal-title":"Lancet"},{"key":"2155_CR3","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1136\/gutjnl-2012-302240","volume":"62","author":"YC Lee","year":"2013","unstructured":"Lee YC, Chen TH, Chiu HM, Shun CT, Chiang H, Liu TY, et al. The benefit of mass eradication of Helicobacter pylori infection: a community-based study of gastric cancer prevention. Gut. 2013;62:676\u201382.","journal-title":"Gut"},{"key":"2155_CR4","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1053\/j.gastro.2016.01.028","volume":"150","author":"YC Lee","year":"2016","unstructured":"Lee YC, Chiang TH, Chou CK, Tu YK, Liao WC, Wu MS, et al. Association between Helicobacter pylori eradication and gastric cancer incidence: a systematic review and meta-analysis. Gastroenterology. 2016;150:1113\u201324.","journal-title":"Gastroenterology"},{"key":"2155_CR5","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1053\/j.gastro.2008.01.071","volume":"134","author":"AC de Vries","year":"2008","unstructured":"de Vries AC, van Grieken NC, Looman CW, Casparie MK, de Vries E, Meijer GA, et al. Gastric cancer risk in patients with premalignant gastric lesions: a nationwide cohort study in the Netherlands. Gastroenterology. 2008;134:945\u201352.","journal-title":"Gastroenterology"},{"key":"2155_CR6","doi-asserted-by":"publisher","first-page":"h3867","DOI":"10.1136\/bmj.h3867","volume":"351","author":"H Song","year":"2015","unstructured":"Song H, Ekheden IG, Zheng Z, Ericsson J, Nyren O, Ye W. Incidence of gastric cancer among patients with gastric precancerous lesions: observational cohort study in a low risk Western population. BMJ. 2015;351:h3867.","journal-title":"BMJ."},{"key":"2155_CR7","doi-asserted-by":"crossref","first-page":"962","DOI":"10.4049\/jimmunol.106.4.962","volume":"106","author":"IM Samloff","year":"1971","unstructured":"Samloff IM. Immunologic studies of human group I pepsinogens. J Immunol. 1971;106:962\u20138.","journal-title":"J Immunol"},{"key":"2155_CR8","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/j.1443-9573.2007.00278.x","volume":"8","author":"K Miki","year":"2007","unstructured":"Miki K, Urita Y. Using serum pepsinogens wisely in a clinical practice. J Dig Dis. 2007;8:8\u201314.","journal-title":"J Dig Dis"},{"key":"2155_CR9","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/0016-5085(82)90176-7","volume":"83","author":"IM Samloff","year":"1982","unstructured":"Samloff IM, Varis K, Ihamaki T, Siurala M, Rotter JI. Relationships among serum pepsinogen I, serum pepsinogen II, and gastric mucosal histology. A study in relatives of patients with pernicious anemia. Gastroenterology. 1982;83:204\u20139.","journal-title":"Gastroenterology."},{"key":"2155_CR10","doi-asserted-by":"publisher","first-page":"e186","DOI":"10.1097\/MCG.0000000000000992","volume":"53","author":"TH Chiang","year":"2019","unstructured":"Chiang TH, Chiu SY, Chen SL, Yen AM, Fann JC, Liu CY, et al. Serum pepsinogen as a predictor for gastric cancer death: a 16-year community-based cohort study. J Clin Gastroenterol. 2019;53:e186\u201393.","journal-title":"J Clin Gastroenterol"},{"key":"2155_CR11","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1111\/j.1443-1661.2009.00839.x","volume":"21","author":"K Miki","year":"2009","unstructured":"Miki K, Fujishiro M. Cautious comparison between East and West is necessary in terms of the serum pepsinogen test. Dig Endosc. 2009;21:134\u20135.","journal-title":"Dig Endosc"},{"key":"2155_CR12","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.cca.2015.11.015","volume":"452","author":"EJ Cho","year":"2016","unstructured":"Cho EJ, Kim HK, Jeong TD, Ko DH, Bae SE, Lee JS, et al. Method evaluation of pepsinogen I\/II assay based on chemiluminescent immunoassays and comparison with other test methods. Clin Chim Acta. 2016;452:149\u201354.","journal-title":"Clin Chim Acta"},{"key":"2155_CR13","doi-asserted-by":"publisher","first-page":"e12393","DOI":"10.1111\/hel.12393","volume":"22","author":"M Leja","year":"2017","unstructured":"Leja M, Camargo MC, Polaka I, Isajevs S, Liepniece-Karele I, Janciauskas D, et al. Detection of gastric atrophy by circulating pepsinogens: a comparison of three assays. Helicobacter. 2017;22:e12393.","journal-title":"Helicobacter."},{"key":"2155_CR14","first-page":"243","volume":"70","author":"TH Chiang","year":"2021","unstructured":"Chiang TH, Chang WJ, Chen SL, Yen AM, Fann JC, Chiu SY, et al. Mass eradication of Helicobacter pylori to reduce gastric cancer incidence and mortality: a long-term cohort study on Matsu Islands. Gut. 2021;70:243\u201350.","journal-title":"Gut"},{"key":"2155_CR15","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1111\/j.1523-5378.2006.00432.x","volume":"11","author":"YC Lee","year":"2006","unstructured":"Lee YC, Wu HM, Chen TH, Liu TY, Chiu HM, Chang CC, et al. A community-based study of Helicobacter pylori therapy using the strategy of test, treat, retest, and re-treat initial treatment failures. Helicobacter. 2006;11:418\u201324.","journal-title":"Helicobacter"},{"key":"2155_CR16","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1136\/gutjnl-2015-310142","volume":"65","author":"JM Liou","year":"2016","unstructured":"Liou JM, Chen CC, Chang CY, Chen MJ, Chen CC, Fang YJ, et al. Sequential therapy for 10 days versus triple therapy for 14 days in the eradication of Helicobacter pylori in the community and hospital populations: a randomised trial. Gut. 2016;65:1784\u201392.","journal-title":"Gut"},{"key":"2155_CR17","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1111\/jgh.15187","volume":"36","author":"TH Chiang","year":"2021","unstructured":"Chiang TH, Maeda M, Yamada H, Chan CC, Chen SL, Chiu SY, et al. Risk stratification for gastric cancer after Helicobacter pylori eradication: a population-based study on Matsu Islands. J Gastroenterol Hepatol. 2021;36:671\u20139.","journal-title":"J Gastroenterol Hepatol"},{"key":"2155_CR18","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.cgh.2010.12.012","volume":"9","author":"AH van Roon","year":"2011","unstructured":"van Roon AH, Wilschut JA, Hol L, van Ballegooijen M, Reijerink JC, t Mannetje H, et al. Diagnostic yield improves with collection of 2 samples in fecal immunochemical test screening without affecting attendance. Clin Gastroenterol Hepatol. 2011;9:333\u20139.","journal-title":"Clin Gastroenterol Hepatol."},{"unstructured":"GastroPanel ELISA. https:\/\/www.biohithealthcare.com\/en\/products\/diagnostic-tests\/gastropanel\/. Accessed 3 Nov 2021.","key":"2155_CR19"},{"key":"2155_CR20","doi-asserted-by":"publisher","first-page":"e12727","DOI":"10.1111\/hel.12727","volume":"25","author":"N Chapelle","year":"2020","unstructured":"Chapelle N, Petryszyn P, Blin J, Leroy M, Le Berre-Scoul C, Jirka I, et al. A panel of stomach-specific biomarkers (GastroPanel\u00ae) for the diagnosis of atrophic gastritis: a prospective, multicenter study in a low gastric cancer incidence area. Helicobacter. 2020;25:e12727.","journal-title":"Helicobacter."},{"unstructured":"Immunological and Serological Reagents \u201cLZ-Test Eiken\u201d. https:\/\/www.eiken.co.jp\/en\/products\/lztest\/ Accessed 3 Nov 2021.","key":"2155_CR21"},{"key":"2155_CR22","doi-asserted-by":"publisher","first-page":"657","DOI":"10.3390\/jcm8050657","volume":"8","author":"CS Bang","year":"2019","unstructured":"Bang CS, Lee JJ, Baik GH. Prediction of chronic atrophic gastritis and gastric neoplasms by serum pepsinogen assay: a systematic review and meta-analysis of diagnostic test accuracy. J Clin Med. 2019;8:657.","journal-title":"J Clin Med."},{"key":"2155_CR23","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1097\/00000478-199610000-00001","volume":"20","author":"MF Dixon","year":"1996","unstructured":"Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol. 1996;20:1161\u201381.","journal-title":"Am J Surg Pathol."},{"key":"2155_CR24","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1136\/gut.2006.106666","volume":"56","author":"M Rugge","year":"2007","unstructured":"Rugge M, Meggio A, Pennelli G, Piscioli F, Giacomelli L, De Pretis G, et al. Gastritis staging in clinical practice: the OLGA staging system. Gut. 2007;56:631\u20136.","journal-title":"Gut"},{"key":"2155_CR25","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1016\/j.gie.2009.12.029","volume":"71","author":"LG Capelle","year":"2010","unstructured":"Capelle LG, de Vries AC, Haringsma J, Ter Borg F, de Vries RA, Bruno MJ, et al. The staging of gastritis with the OLGA system by using intestinal metaplasia as an accurate alternative for atrophic gastritis. Gastrointest Endosc. 2010;71:1150\u20138.","journal-title":"Gastrointest Endosc"},{"key":"2155_CR26","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/j.bpg.2015.09.009","volume":"29","author":"L Rabeneck","year":"2015","unstructured":"Rabeneck L, Lansdorp-Vogelaar I. Assessment of a cancer screening program. Best Pract Res Clin Gastroenterol. 2015;29:979\u201385.","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"2155_CR27","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.gie.2019.05.034","volume":"90","author":"MC Tan","year":"2019","unstructured":"Tan MC, Graham DY. Gastric cancer risk stratification and surveillance after Helicobacter pylori eradication: 2020. Gastrointest Endosc. 2019;90:457\u201360.","journal-title":"Gastrointest Endosc"},{"key":"2155_CR28","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1053\/j.gastro.2014.08.043","volume":"147","author":"TH Chiang","year":"2014","unstructured":"Chiang TH, Chuang SL, Chen SL, Chiu HM, Yen AM, Chiu SY, et al. Difference in performance of fecal immunochemical tests with the same hemoglobin cutoff concentration in a nationwide colorectal cancer screening program. Gastroenterology. 2014;147:1317\u201326.","journal-title":"Gastroenterology"},{"key":"2155_CR29","doi-asserted-by":"publisher","first-page":"5133","DOI":"10.21873\/anticanres.11083","volume":"36","author":"K Syrjanen","year":"2016","unstructured":"Syrjanen K. A panel of serum biomarkers (GastroPanel\u00ae) in non-invasive diagnosis of atrophic gastritis. Systematic review and meta-analysis. Anticancer Res. 2016;36:5133\u201344.","journal-title":"Anticancer Res."},{"key":"2155_CR30","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1136\/gutjnl-2016-312288","volume":"66","author":"P Malfertheiner","year":"2017","unstructured":"Malfertheiner P, Megraud F, O\u2019Morain CA, Gisbert JP, Kuipers EJ, Axon AT, et al. Management of Helicobacter pylori infection-the Maastricht V\/Florence Consensus Report. Gut. 2017;66:6\u201330.","journal-title":"Gut"},{"key":"2155_CR31","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1136\/gutjnl-2020-322368","volume":"69","author":"JM Liou","year":"2020","unstructured":"Liou JM, Malfertheiner P, Lee YC, Sheu BS, Sugano K, Cheng HC, et al. Screening and eradication of Helicobacter pylori for gastric cancer prevention: the Taipei global consensus. Gut. 2020;69:2093\u2013112.","journal-title":"Gut"},{"key":"2155_CR32","doi-asserted-by":"publisher","first-page":"147","DOI":"10.2188\/jea.JE20170094","volume":"29","author":"S Kikuchi","year":"2019","unstructured":"Kikuchi S, Kato M, Mabe K, Kawai T, Furuta T, Inoue K, et al. Optimal criteria and diagnostic ability of serum pepsinogen values for Helicobacter pylori infection. J Epidemiol. 2019;29:147\u201354.","journal-title":"J Epidemiol"},{"key":"2155_CR33","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1136\/gutjnl-2014-307094","volume":"64","author":"K Asada","year":"2015","unstructured":"Asada K, Nakajima T, Shimazu T, Yamamichi N, Maekita T, Yokoi C, et al. Demonstration of the usefulness of epigenetic cancer risk prediction by a multicentre prospective cohort study. Gut. 2015;64:388\u201396.","journal-title":"Gut"},{"key":"2155_CR34","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1136\/gutjnl-2020-322065","volume":"70","author":"JBY So","year":"2021","unstructured":"So JBY, Kapoor R, Zhu F, Koh C, Zhou L, Zou R, et al. Development and validation of a serum microRNA biomarker panel for detecting gastric cancer in a high-risk population. Gut. 2021;70:829\u201337.","journal-title":"Gut"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-022-02155-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-022-02155-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-022-02155-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T11:44:54Z","timestamp":1674819894000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-022-02155-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,18]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2155"],"URL":"https:\/\/doi.org\/10.1186\/s12876-022-02155-7","relation":{},"ISSN":["1471-230X"],"issn-type":[{"type":"electronic","value":"1471-230X"}],"subject":[],"published":{"date-parts":[[2022,2,18]]},"assertion":[{"value":"13 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All study procedures were in accordance with the ethical standards of the responsible committee on human experimentation and with the Helsinki Declaration of 1964 and later versions. The study protocol was approved by the Institutional Review Board\u00a0(IRB) of National Taiwan University Hospital (IRB No: 201406021RINA). Informed consent was obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None of the authors have commercial affiliations that constitute any conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"69"}}